Frontier Medicines launches with $67M and biotech veteran Varma as CEO

He’s founded and led a handful of biotechs and put in time at multiple venture capital firms. Chris Varma’s latest project? Drugging the undruggable to bring forth treatments against “debilitating diseases, starting with cancer.”

Varma leads Frontier Medicines, which launched Tuesday with $67 million in series A funding. The company aims to solve a problem that has plagued the biopharma industry since the beginning.

Continue reading on FierceBiotech

By MIT Sloan CDO
MIT Sloan CDO